Research from Redeye, Redeye AB

Redeye

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen). 

Expertise in Denmark, Finland, Norway and Sweden.

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye comments on Alzinova's announcement that it has completed its research collaboration with Amsterdam UMC within the company's blood-based Alzheimer's diagnostic program.</li><li>The study confirmed measurable antibody signals against toxic amyloid-β oligomers in human serum, and lower reactivity in Alzheimer's patients than in age-matched controls.</li><li>We view the outcome as encouraging as it confirms earlier observations in an independent sample set and meets the condition set out in the Letter of Intent with Fujirebio.</li></ul>

Redeye comments on Alzinova's announcement that it has completed its research collaboration with Amsterdam UMC within the company's blood-based Alzheimer's diagnostic program.The study confirmed measurable antibody signals against toxic amyloid-β oligomers in human serum, and lower reactivity in Alzheimer's patients than in age-matched controls.We view the outcome as encouraging as it confirms earlier observations in an independent sample set and meets the condition set out in the Letter of Intent with Fujirebio.

Alzinova: Encouraging results from Diagnostics study